Goldman Sachs initiated coverage of 89bio (ETNB) with a Neutral rating and $11 price target 89bio is a late-stage clinical company focused on ...

Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough Therapy designation from FDA for MASH Clearance of Investigation ...

Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received ...

Explore SGMT's breakthrough MASH therapy, Denifanstat, with FDA designation & Phase 3 progress. Click here to read my most ...

Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a ...

Q4 2024 Earnings Call Transcript February 27, 2025 Altimmune, Inc. beats earnings expectations. Reported EPS is $-0.33, ...

Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study -- -- Completed ...

ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to ...

Cases of MASH with clinically significant fibrosis (F stage of ≥ F2, centrilobular and periportal fibrosis, or more severe disease) are predicted to increase from 6.7 million in 2020 to 11.7 ...

Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and revenue expectations.